Misdiagnosis of Sepsis in Patients with Acutely Decompensated Heart Failure. Real World Outcomes

Abstract

worsened PAH was identified in 83 (13.1%) cases. In the dasatinib PAH group (n=75, 90.4% of all PAH), mean age was 54.95 years and there were 45 (60%) women. In the nilotinib PAH group (n=3, 6% of all PAH), mean age was 69 years and there was 1 (33%) woman. In the imatinib PAH group (n=5, 3.6% of all PAH), mean age was 49.6 years and there were 3 (60%) women. Conclusions: Patients treated with TKIs, especially dasatinib, may develop PAH while the incidence of PAH with nilotinib and imatinib appears to be low. Further research is warranted to cover the gap of screening guidelines, which challenges the detection of CML patients treated with TKIs who develop PAH. As comparable outcomes are reported with first line therapy, in patients at risk for PAH, clinicians can opt for the therapy with decreased association with the syndrome.